These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 6185345)
1. Immunogenic variants obtained by mutagenesis of mouse Lewis lung carcinoma. Recognition of variant-specific antigens by cytolytic T lymphocytes. Vessière F; Georlette M; Warnier G; Leclerc JC; Van Pel A; Boon T Eur J Cancer Clin Oncol; 1982 Sep; 18(9):867-74. PubMed ID: 6185345 [TBL] [Abstract][Full Text] [Related]
2. Tumour cell variants with increased immunogenicity obtained by mutagen treatment. Boon T; Maryanski J Cancer Surv; 1985; 4(1):135-48. PubMed ID: 3879855 [TBL] [Abstract][Full Text] [Related]
3. Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice. Van Pel A; Georlette M; Boon T Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5282-5. PubMed ID: 291945 [TBL] [Abstract][Full Text] [Related]
4. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. Maryanski JL; Boon T Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608 [TBL] [Abstract][Full Text] [Related]
5. Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation. Peppoloni S; Herberman RB; Gorelik E Cancer Res; 1985 Jun; 45(6):2560-6. PubMed ID: 2580624 [TBL] [Abstract][Full Text] [Related]
6. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Maryanski JL; Van Snick J; Cerottini JC; Boon T Eur J Immunol; 1982 May; 12(5):401-6. PubMed ID: 6178607 [TBL] [Abstract][Full Text] [Related]
7. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. Maryanski JL; Marchand M; Uyttenhove C; Boon T Int J Cancer; 1983 Jan; 31(1):119-23. PubMed ID: 6187698 [TBL] [Abstract][Full Text] [Related]
8. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level. Sensi M; Orosz CG; Bach FH J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778 [TBL] [Abstract][Full Text] [Related]
9. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. Van Pel A; Vessière F; Boon T J Exp Med; 1983 Jun; 157(6):1992-2001. PubMed ID: 6602203 [TBL] [Abstract][Full Text] [Related]
10. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Wölfel T; Van Pel A; De Plaen E; Lurquin C; Maryanski JL; Boon T Immunogenetics; 1987; 26(3):178-87. PubMed ID: 3114137 [TBL] [Abstract][Full Text] [Related]
11. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Van Waes C; Monach PA; Urban JL; Wortzel RD; Schreiber H Tissue Antigens; 1996 May; 47(5):399-407. PubMed ID: 8795140 [TBL] [Abstract][Full Text] [Related]
12. Recognition of Rous sarcoma virus-induced tumor antigens by cytotoxic T lymphocytes (CTL): studies on specificity of killing by CTL employing H-2 congenic and recombinant mouse tumor cells. Haraguchi S; Kurakata S; Fujii T; Matsuo T; Yoshida TO Cell Immunol; 1987 Apr; 105(2):340-54. PubMed ID: 2436809 [TBL] [Abstract][Full Text] [Related]
13. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids. Maryanski JL; Szpirer J; Szpirer C; Boon T Somatic Cell Genet; 1983 May; 9(3):345-57. PubMed ID: 6407125 [TBL] [Abstract][Full Text] [Related]
14. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens. Fuji H; Iribe H Cancer Res; 1986 Nov; 46(11):5541-7. PubMed ID: 3489524 [TBL] [Abstract][Full Text] [Related]
15. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens. Van Snick J; Maryanski J; Van Pel A; Parmiani G; Boon T Eur J Immunol; 1982 Nov; 12(11):905-8. PubMed ID: 6818041 [TBL] [Abstract][Full Text] [Related]
16. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. Boon T; Van Snick J; Van Pel A; Uyttenhove C; Marchand M J Exp Med; 1980 Nov; 152(5):1184-93. PubMed ID: 6776227 [TBL] [Abstract][Full Text] [Related]
17. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones. Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090 [TBL] [Abstract][Full Text] [Related]
18. Differences in cell surface antigens of tumor metastases and those of the local tumor. Fogel M; Gorelik E; Segal S; Feldman M J Natl Cancer Inst; 1979 Mar; 62(3):585-8. PubMed ID: 84091 [TBL] [Abstract][Full Text] [Related]
19. Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815. Marchand M; Caspar P; Boon T Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1529-37. PubMed ID: 6196202 [TBL] [Abstract][Full Text] [Related]
20. New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells. von Hoegen P; Altevogt P; Schirrmacher V Cell Immunol; 1987 Oct; 109(2):338-48. PubMed ID: 3117377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]